Status:
COMPLETED
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
Lead Sponsor:
Amgen
Collaborating Sponsors:
Immunex Corporation
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of long-term administration of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. ...
Eligibility Criteria
Inclusion
- \- Subjects who were randomized and received at least one dose of investigational product in Study 20021639 or 20021642 (provided that they meet all inclusion/exclusion criteria of this protocol)
Exclusion
- Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit
- Pregnant or breast-feeding females
- Evidence of skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of the investigational product on psoriasis
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
912 Patients enrolled
Trial Details
Trial ID
NCT00111436
Start Date
April 1 2003
End Date
July 1 2005
Last Update
April 26 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.